Regulatory Approval Delays
Could impact market entry and revenue
- Materiality
- high
Cinclus Pharma Holding
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD). Established in Stockholm, the company is publicly listed on Nasdaq Stockholm and is advancing its drug candidate, linaprazan glurate, through clinical trials. Cinclus Pharma aims to address significant unmet medical needs in acid-related diseases through its specialized drug development efforts.
21
3.92
3.72
| % | |
|---|---|
| Pharmaceutical Development | 70% Development of new drug candidates for acid-related diseases |
| Clinical Trials | 20% Management and execution of clinical trials for drug candidates |
| Regulatory Strategy | 10% Development of strategies for regulatory approval and compliance |
Cinclus Pharma primarily serves healthcare providers and pharmaceutical distributors who require innovative treatments...
- Healthcare Providersprimary
Purchase GERD treatments for patient care
- Pharmaceutical Distributorssecondary
Distribute innovative drugs to healthcare systems
- Research Institutionsemerging
Collaborate on clinical trials and drug development
Cinclus Pharma is headquartered in Stockholm, Sweden, and operates primarily within the European market...
- •Headquartered in Stockholm, Sweden
- •Primary operations in the European market
- •Exploring expansion opportunities in other regions
- •Strategic location for accessing key healthcare ecosystems
Cinclus Pharma's strategic priorities include advancing its lead drug candidate, linaprazan glurate, through Phase III...
01
Advance Phase III Trialsmedium-term
To bring linaprazan glurate to market
02
Regulatory Approvalsmedium-term
To ensure market entry and compliance
03
Geographic Expansionlong-term
To access new markets and increase revenue
Cinclus Pharma faces several risks, including regulatory hurdles that could delay drug approvals and market entry...
Market Acceptance
Depends on perceived effectiveness of new drugs
- Materiality
- high
Equity Financing Reliance
May not be sustainable long-term
- Materiality
- medium
Competitive Landscape
Larger companies may develop similar treatments
- Materiality
- medium
Revenue Recognition
Drug Development Costs
IFRS 16
Lease Accounting (IFRS 16)
Estimates and Provisions
Camurus
CAMX.ST · Health Care
Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases.
CUMBERLAND PHARMACEUTICALS INC
CPIX · Pharmaceutical Preparations
EQL Pharma
EQL.ST · Health Care
EQL Pharma is a pharmaceutical company focused on developing and selling generic prescription drugs and medical tests.
Vimian Group
VIMIAN.ST · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Acurx Pharmaceuticals, Inc.
ACXP · Pharmaceutical Preparations
Mirum Pharmaceuticals, Inc.
MIRM · Pharmaceutical Preparations
Mirum Pharmaceuticals is a U.S.-based biopharmaceutical company focused on rare diseases, with a commercial portfolio centered on bile acid and cholestatic liver disorder therapies.
: 11/08/2026